Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Real-World Treatment Patterns in Patients with Mycosis Fungoides or Sézary Syndrome Treated with Mogamulizumab in the United States: A Retrospective Database Analysis

Bradley M. Haverkos, Chunlan Chang, Robert Ristuccia, Yutong Chang, Jennifer Friderici, Sima Rozati

Blood (2024) 144 (Supplement 1): 4437.

https://doi.org/10.1182/blood-2024-198022

Published: 2024

Journal Articles

TP53 -Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers

Blood (2024) 144 (Supplement 1): 6451.

https://doi.org/10.1182/blood-2024-194844

Published: 2024

Journal Articles

Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort

Blood (2024) 144 (Supplement 1): 982.

https://doi.org/10.1182/blood-2024-194242

Published: 2024

Journal Articles

Identifying Novel Epigenetic Therapies for T-Cell Lymphomas By High Throughput Drug Screen

Bradley M. Haverkos, Xander Bradeen, Bianca Labuschagne, Mason Kragenbring, Eduardo Davila

Blood (2024) 144 (Supplement 1): 5839.

https://doi.org/10.1182/blood-2024-211152

Published: 2024

Journal Articles

Preliminary Safety and Tolerability of CD19x22 CAR-T Cell Therapy in Adolescent and Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Manali K. Kamdar, Bradley M. Haverkos, Alexander W. Rankin, Cheri Adams, Michael R Verneris, Andrew Roth, Kimberly Jordan, Navin R. Pinto, M. Eric Kohler, Angela Ohm, Terry J Fry

Blood (2024) 144 (Supplement 1): 4510.

https://doi.org/10.1182/blood-2024-210123

Published: 2024

Journal Articles

Asparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 1690.

https://doi.org/10.1182/blood-2024-211424

Published: 2024

Journal Articles

Targeting EBV Encoded Viral Kinases with GCV, AZT, Rituximab and Dexamethasone (GARD) Results in Durable Responses in Patients with CNS Lymphoproliferative Disease

Haley L. Klimaszewski, Christoph Weigel, Selamawit Addissie, Sarah Schlotter, Tounkara Fode, James P. Dugan, Bradley M. Haverkos, Lynda Villagomez, Mark Lustberg, Pierluigi Porcu, Timothy Voorhees, Michael A Caligiuri, Christopher C. Oakes, Ginny Bumgardner, Robert Baiocchi

Blood (2023) 142 (Supplement 1): 4476.

https://doi.org/10.1182/blood-2023-189618

Published: 2023

Journal Articles

Outcomes of Haplo-Cord and Dual-Cord Transplants: A Single-Center Retrospective Analysis

Michael K Jones, Andrew Kent, Kellen Gil, Enkhtsetseg Purev, Bradley M. Haverkos, Marc Schwartz, Christine M. McMahon, Maria L Amaya, Grace N Bosma, Rachel Rabinovitch, Daniel A. Pollyea, Jonathan A Gutman

Blood (2023) 142 (Supplement 1): 7084.

https://doi.org/10.1182/blood-2023-190558

Published: 2023

Journal Articles

CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas

Blood (2022) 140 (Supplement 1): 1481–1484.

https://doi.org/10.1182/blood-2022-160090

Published: 2022

Journal Articles

Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions

Blood (2022) 140 (Supplement 1): 1328–1331.

https://doi.org/10.1182/blood-2022-157829

Published: 2022

Journal Articles

The Impact of Chemotherapy on Phenotype and Function of Non-Malignant T-Cells in Patients with T-Cell Lymphoma

Meryl Colton, Kimberly Jordan, Eduardo Davila, Xander Bradeen, Jasmine Zain, Pierluigi Porcu, Bradley M. Haverkos

Blood (2022) 140 (Supplement 1): 11938–11940.

https://doi.org/10.1182/blood-2022-169691

Published: 2022

Journal Articles

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series

Blood (2022) 140 (Supplement 1): 3839–3841.

https://doi.org/10.1182/blood-2022-157105

Published: 2022

Journal Articles

Results from a Phase I Trial Using Nivolumab in Combination with Dose Adjusted EPOCH in Newly Diagnosed Peripheral T-Cell Lymphomas

Bradley M. Haverkos, Jasmine Zain, Manali K. Kamdar, Alexander Neuwelt, Eduardo Davila, Xander Bradeen, Steven M. Bair, Jagar Jasem, Emily Berens, Clayton Smith, Diana Abbott, Pierluigi Porcu

Blood (2022) 140 (Supplement 1): 2308–2309.

https://doi.org/10.1182/blood-2022-168979

Published: 2022

Journal Articles

Nanatinostat (Nstat) and Valganciclovir (VGCV) in Relapsed/Refractory (R/R) Epstein-Barr Virus-Positive (EBV + ) Lymphomas: Final Results from the Phase 1b/2 VT3996-201 Study

Bradley M. Haverkos, Onder Alpdogan, Robert Baiocchi, Jonathan E Brammer, Tatyana A. Feldman, Marcelo Capra, Elizabeth A Brem, Santosh M Nair, Phillip Scheinberg, Juliana Pereira, Leyla Shune, Erel Joffe, Afton Katkov, Robert McRae, Ivor Royston, Lisa Rojkjaer, Pierluigi Porcu

Blood (2021) 138 (Supplement 1): 623.

https://doi.org/10.1182/blood-2021-152603

Published: 2021

Journal Articles

Addition of Rituximab to High-Dose Methotrexate Regimens Improves Complete Response Rates and Median Overall Survival in Non-Germinal Center Primary CNS Lymphoma

Neelam Mistry, MD, Derek E Smith, MS, Manali Kamdar, MD, Bradley M. Haverkos, MD MPH, MS, Douglas Ney, MD

Blood (2018) 132 (Supplement 1): 4217.

https://doi.org/10.1182/blood-2018-99-112686

Published: 2018

Journal Articles

Pooled Safety Analysis and Efficacy of Tenalisib (RP6530), a PI3Kδ/γ Inhibitor, in Patients with Relapsed/Refractory Lymphoid Malignancies

Swami P. Iyer, MD, Auris Huen, MD, Andres J M Ferreri, MD, Bradley M. Haverkos, MD MPH, MS, Jasmine M. Zain, MD, Radhakrishnan Ramchandren, MD, Mary Jo Lechowicz, MD, Sumana Devata, MD, Neil Korman, MD, Lauren C. Pinter-Brown, MD, Richard Delarue, MD, Kasi V Routhu, PhD, Prajak Barde, MD, Ajit M Nair, PhD, Carmelo Carlo-Stella, MD

Blood (2018) 132 (Supplement 1): 2925.

https://doi.org/10.1182/blood-2018-99-112757

Published: 2018

Journal Articles

Phase I/II Study of CHOEP Plus Lenalidomide As Initial Therapy for Patients with Stage II-IV Peripheral T-Cell Lymphoma: Phase II Results

Matthew A. Lunning, DO, Steven M. Horwitz, MD, Ranjana Advani, MD, Julie M. Vose, MDMBA, Hun Ju Lee, MD, Neha Mehta-Shah, MD, Jasmine M. Zain, MD, Bradley M. Haverkos, MD MPH, MS, Mary Jo Lechowicz, MD, Alison J. Moskowitz, MD, Luu Q. Pham, Elizabeth R. Lyden, MS, Peggy Heires, R.N., Stephen M. Ansell, MD PhD

Blood (2018) 132 (Supplement 1): 2899.

https://doi.org/10.1182/blood-2018-99-114110

Published: 2018

Journal Articles

Phase 1 Trial of Cobomarsen, an Inhibitor of Mir-155, in Cutaneous T Cell Lymphoma

Blood (2018) 132 (Supplement 1): 2903.

https://doi.org/10.1182/blood-2018-99-119861

Published: 2018

Journal Articles

Post Transplant Prophylaxis with High Dose Valacyclovir through Day 100 Versus Day of Post Transplant Hospital Discharge Decreases Cytomegalovirus Reactivation in Adult Umbilical Cord Blood Transplant Recipients

Prashant Sharma, MD, Jennifer MacDonald, Jeff Kaiser, Jennifer Tobin, Matthew Miller, Maheen Abidi, MD, Esther Benamu, MD, Enkhtsetseg Purev, MD PhD, Bradley M. Haverkos, MD MPH, MS, Jonathan A Gutman, MD

Blood (2018) 132 (Supplement 1): 4659.

https://doi.org/10.1182/blood-2018-99-110211

Published: 2018

Journal Articles

Chronic Graft Versus Host Disease Burden and Relapse Rates Are Lower with Comparable Overall Survival and Graft Versus Host Disease Free, Relapse Free Survival Following Adult Umbilical Cord Blood Compared to Matched Sibling Peripheral Blood Stem Cell Transplantation

Prashant Sharma, MD, Enkhtsetseg Purev, MD PhD, Bradley M. Haverkos, MD MPH, MS, Daniel A Pollyea, MD, Clayton Smith, MD, Manali Kamdar, Daniel W Sherbenou, MD PhD, Tomer M Mark, MD MS, Peter A Forsberg, MD, Jonathan A Gutman, MD

Blood (2018) 132 (Supplement 1): 4660.

https://doi.org/10.1182/blood-2018-99-119690

Published: 2018

NARROW

Real-World Treatment Patterns in Patients with Mycosis Fungoides or Sézary Syndrome Treated with Mogamulizumab in the United States: A Retrospective Database Analysis

TP53 -Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers

Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort

Identifying Novel Epigenetic Therapies for T-Cell Lymphomas By High Throughput Drug Screen

Preliminary Safety and Tolerability of CD19x22 CAR-T Cell Therapy in Adolescent and Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Asparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study

Targeting EBV Encoded Viral Kinases with GCV, AZT, Rituximab and Dexamethasone (GARD) Results in Durable Responses in Patients with CNS Lymphoproliferative Disease

Outcomes of Haplo-Cord and Dual-Cord Transplants: A Single-Center Retrospective Analysis

CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas

Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions

The Impact of Chemotherapy on Phenotype and Function of Non-Malignant T-Cells in Patients with T-Cell Lymphoma

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series

Results from a Phase I Trial Using Nivolumab in Combination with Dose Adjusted EPOCH in Newly Diagnosed Peripheral T-Cell Lymphomas

Nanatinostat (Nstat) and Valganciclovir (VGCV) in Relapsed/Refractory (R/R) Epstein-Barr Virus-Positive (EBV + ) Lymphomas: Final Results from the Phase 1b/2 VT3996-201 Study

Addition of Rituximab to High-Dose Methotrexate Regimens Improves Complete Response Rates and Median Overall Survival in Non-Germinal Center Primary CNS Lymphoma

Pooled Safety Analysis and Efficacy of Tenalisib (RP6530), a PI3Kδ/γ Inhibitor, in Patients with Relapsed/Refractory Lymphoid Malignancies

Phase I/II Study of CHOEP Plus Lenalidomide As Initial Therapy for Patients with Stage II-IV Peripheral T-Cell Lymphoma: Phase II Results

Phase 1 Trial of Cobomarsen, an Inhibitor of Mir-155, in Cutaneous T Cell Lymphoma

Post Transplant Prophylaxis with High Dose Valacyclovir through Day 100 Versus Day of Post Transplant Hospital Discharge Decreases Cytomegalovirus Reactivation in Adult Umbilical Cord Blood Transplant Recipients

Chronic Graft Versus Host Disease Burden and Relapse Rates Are Lower with Comparable Overall Survival and Graft Versus Host Disease Free, Relapse Free Survival Following Adult Umbilical Cord Blood Compared to Matched Sibling Peripheral Blood Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only